SARS-CoV-2 immune responses in lymphoma patients
Official title: SARS-CoV-2 immune responses in patients with lymphoma
Funded at Emory University · NIH-11384773 · Data updated 2026-11-12
This grant studies how people with lymphoma respond to COVID-19 vaccines and infection, aiming to understand why antibody and T cell responses can be weaker in NHL/CLL patients.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project start | August 23, 2024 |
| Project end | July 31, 2029 |
| Funding year | 2026 |
| Award (this year) | $192,888 |
| NIH project number | 5K08AI178093-03 |
| Project ID | NIH-11384773 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with non-Hodgkin lymphoma or chronic lymphocytic leukemia who have received lymphoma-directed therapies.
✕Less likely to help
Patients without NHL/CLL or those not receiving relevant therapies may not benefit from this specific research focus.
What this research studies
This project follows patients with non-Hodgkin lymphoma or chronic lymphocytic leukemia who have immune system challenges due to cancer and its treatments. It uses a large cohort of over 600 patients and more than 1,300 blood samples to examine how vaccines spark antibodies and T cells. The researchers will look at both antibody levels and antigen-specific T cell responses over time after vaccination or infection. The goal is to uncover patterns that explain reduced vaccine effectiveness and to guide better vaccination strategies for these patients.
Why it matters
Potential benefit: Insights could lead to improved vaccination approaches and better protection for NHL/CLL patients.
How similar studies have gone: Previous work showed reduced antibody responses and some T cell responses after vaccination in NHL/CLL patients, with longitudinal characterization still needed.
Where this research is happening
-
Emory University
Atlanta, United States Active
Researchers
- Principal investigator: Chang, Andres — Emory University
- Study coordinator: Chang, Andres
Related research
Other NIH-funded projects on the same topics.
-
Understanding immune responses to SARS-CoV-2 in lymphoma patients
This study is looking at how well people with non-Hodgkin lymphoma and chronic lymphocytic leukemia respond to COVID-19 vaccines, to better understand their immune responses and help improve vaccination strategies for them.
-
How COVID-19 infection and genes may influence memory and dementia risk
This study looks at how getting COVID-19 and a person’s genes together affect the chance of developing memory problems and Alzheimer’s disease later in life.
-
Understanding flu and COVID-19 vaccine responses in people and in the lab
Researchers at Stanford explore how flu and COVID-19 vaccines work in people and in lab tests to improve protection for adults.
-
Oral small molecule inhibitors to block SARS-CoV-2 RNA replication
A Stanford-led project tests a pill that could stop SARS-CoV-2 and related viruses from copying their RNA inside infected cells.
-
Outpatient antiviral cocktails to fight SARS-CoV-2 and future RNA viruses
Researchers at Stanford are developing outpatient antiviral cocktails that could be used easily outside the hospital to treat COVID-19 and future RNA virus infections.
-
Understanding why Black and Hispanic Hodgkin lymphoma patients have worse survival
A patient-centered study to uncover social and care factors that contribute to lower survival among Black and Hispanic people with Hodgkin lymphoma across all ages.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.